In addition, we revealed and experimentally validated the previously unknown MoA of a repurposed drug (JNK-IN-5A) for non-alcoholic fatty liver disease via Open MoA. This evidence concerns the gene MAPK8 and metabolic dysfunction-associated steatotic liver disease.